DK0679187T4 - Fremgangsmåde til udvinding af native, oligomere, glycosylerede ektodomæner fra virale membranproteiner, og deres anvendelse, især som vaccine mod HIV - Google Patents

Fremgangsmåde til udvinding af native, oligomere, glycosylerede ektodomæner fra virale membranproteiner, og deres anvendelse, især som vaccine mod HIV

Info

Publication number
DK0679187T4
DK0679187T4 DK94904568T DK94904568T DK0679187T4 DK 0679187 T4 DK0679187 T4 DK 0679187T4 DK 94904568 T DK94904568 T DK 94904568T DK 94904568 T DK94904568 T DK 94904568T DK 0679187 T4 DK0679187 T4 DK 0679187T4
Authority
DK
Denmark
Prior art keywords
protein
pct
native
ectodomains
glycosylated
Prior art date
Application number
DK94904568T
Other languages
English (en)
Other versions
DK0679187T3 (da
Inventor
Manfred Schawaller
Original Assignee
Manfred Schawaller
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=6478309&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0679187(T4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Manfred Schawaller filed Critical Manfred Schawaller
Publication of DK0679187T3 publication Critical patent/DK0679187T3/da
Application granted granted Critical
Publication of DK0679187T4 publication Critical patent/DK0679187T4/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DK94904568T 1993-01-16 1994-01-12 Fremgangsmåde til udvinding af native, oligomere, glycosylerede ektodomæner fra virale membranproteiner, og deres anvendelse, især som vaccine mod HIV DK0679187T4 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4301017 1993-01-16
PCT/DE1994/000022 WO1994016081A1 (de) 1993-01-16 1994-01-12 Verfahren zur gewinnung nativer domänen viraler membranproteine, deren verwendung, insbesondere als impfstoff gegen hiv

Publications (2)

Publication Number Publication Date
DK0679187T3 DK0679187T3 (da) 1997-12-08
DK0679187T4 true DK0679187T4 (da) 2001-09-17

Family

ID=6478309

Family Applications (1)

Application Number Title Priority Date Filing Date
DK94904568T DK0679187T4 (da) 1993-01-16 1994-01-12 Fremgangsmåde til udvinding af native, oligomere, glycosylerede ektodomæner fra virale membranproteiner, og deres anvendelse, især som vaccine mod HIV

Country Status (9)

Country Link
US (1) US6140059A (da)
EP (1) EP0679187B2 (da)
JP (1) JP3658690B2 (da)
AT (1) ATE153380T1 (da)
DE (2) DE59402827D1 (da)
DK (1) DK0679187T4 (da)
ES (1) ES2102815T5 (da)
GR (1) GR3023717T3 (da)
WO (1) WO1994016081A1 (da)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2781676B1 (fr) * 1998-07-31 2004-04-02 Pasteur Merieux Serums Vacc Trimere du produit d'expression du gene env de hiv
EP1141314A2 (en) 1998-12-31 2001-10-10 Chiron Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
ATE384795T1 (de) 1998-12-31 2008-02-15 Novartis Vaccines & Diagnostic Modifizierte hiv env polypeptide
CA2360347C (en) 1998-12-31 2013-05-07 Chiron Corporation Improved expression of hiv polypeptides and production of virus-like particles
US7935805B1 (en) * 1998-12-31 2011-05-03 Novartis Vaccines & Diagnostics, Inc Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof
CA2384271A1 (en) * 1999-09-17 2001-03-22 Joseph G. Sodroski Stabilized soluble glycoprotein trimers
US7179468B1 (en) 2000-06-08 2007-02-20 Cornell Research Foundation, Inc. Antigen for developing neutralizing antibodies to human immunodeficiency virus
EP1409694A4 (en) * 2001-07-05 2006-02-08 Chiron Corp POLYNUCLEOTIDES ENCODING ANTIGENIC POLYPEPTIDES OF HIV SUBTYPE B AND / OR SUBTYPE C, POLYPEPTIDES AND USES THEREOF
AU2002320314A1 (en) 2001-07-05 2003-01-21 Chiron, Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
AU2002316578A1 (en) * 2001-08-31 2003-03-18 Chiron Corporation Polynucleotides encoding antigenic hiv type b polypeptides, polypeptides and uses thereof
US20030170614A1 (en) * 2001-08-31 2003-09-11 Megede Jan Zur Polynucleotides encoding antigenic HIV type B polypeptides, polypeptides and uses thereof
JP2007502623A (ja) * 2003-05-09 2007-02-15 リサーチ ディベロップメント ファウンデーション 膜タンパク質におけるフリンプロテアーゼ開裂部位の挿入およびその使用法
US7358334B1 (en) 2003-11-14 2008-04-15 Jay W Chaplin B cell-targeted toxins for humoral immune response reduction and methods of use thereof
US7951384B2 (en) * 2005-08-05 2011-05-31 University Of Massachusetts Virus-like particles as vaccines for paramyxovirus
US9216212B2 (en) * 2005-08-05 2015-12-22 University Of Massachusetts Virus-like particles as vaccines for paramyxovirus
WO2010039224A2 (en) * 2008-09-30 2010-04-08 University Of Massachusetts Medical School Respiratory syncytial virus (rsv) sequences for protein expression and vaccines
ES2635080T3 (es) 2009-03-10 2017-10-02 Baylor Research Institute Vacunas contra el cáncer dirigidas a células presentadoras de antígenos
DK2406286T3 (da) 2009-03-10 2016-08-22 Baylor Res Inst Anti-cd40-antistoffer og anvendelser deraf
DK2406288T3 (da) 2009-03-10 2017-03-27 Baylor Res Inst Antigen præsenterende celle-målrettede vacciner
EP3187585A1 (en) 2010-03-25 2017-07-05 Oregon Health&Science University Cmv glycoproteins and recombinant vectors
WO2012135132A1 (en) 2011-03-25 2012-10-04 Baylor Research Institute Compositions and methods to immunize against hepatitis c virus
DK2691530T3 (da) 2011-06-10 2018-05-22 Univ Oregon Health & Science Cmv-glycoproteiner og rekombinante vektorer
EP2586461A1 (en) 2011-10-27 2013-05-01 Christopher L. Parks Viral particles derived from an enveloped virus
EP2679596B1 (en) 2012-06-27 2017-04-12 International Aids Vaccine Initiative HIV-1 env glycoprotein variant
EP2848937A1 (en) 2013-09-05 2015-03-18 International Aids Vaccine Initiative Methods of identifying novel HIV-1 immunogens
EP2873423B1 (en) 2013-10-07 2017-05-31 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
CN106103483A (zh) 2014-01-13 2016-11-09 贝勒研究院 抗hpv和hpv相关的疾病的新疫苗
US10174292B2 (en) 2015-03-20 2019-01-08 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
EP3072901A1 (en) 2015-03-23 2016-09-28 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
US10610585B2 (en) 2017-09-26 2020-04-07 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and compositions for treating and preventing HIV

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3731874A1 (de) * 1987-09-18 1989-03-30 Schering Ag Verfahren zur herstellung von peptiden durch spezifische spaltung von gentechnisch gewonnenen fusionsproteinen mit collagenasen
IL89567A0 (en) * 1988-03-28 1989-09-10 Univ Leland Stanford Junior Mutated hiv envelope protein
EP0519001B2 (en) † 1990-03-09 2007-12-19 Novartis Vaccines and Diagnostics, Inc. PURIFIED gp120 COMPOSITION RETAINING NATURAL CONFORMATION
FR2676071B1 (fr) * 1991-05-02 1994-11-18 Transgene Sa Nouveau variant gp160 non-clivable, soluble, de forme hybride.

Also Published As

Publication number Publication date
DK0679187T3 (da) 1997-12-08
JP3658690B2 (ja) 2005-06-08
ES2102815T5 (es) 2001-11-16
GR3023717T3 (en) 1997-09-30
WO1994016081A1 (de) 1994-07-21
JPH08505769A (ja) 1996-06-25
DE4400659A1 (de) 1994-07-21
EP0679187B1 (de) 1997-05-21
ES2102815T3 (es) 1997-08-01
US6140059A (en) 2000-10-31
DE59402827D1 (de) 1997-06-26
DE4400659C2 (de) 1995-07-27
EP0679187B2 (de) 2001-07-04
EP0679187A1 (de) 1995-11-02
ATE153380T1 (de) 1997-06-15

Similar Documents

Publication Publication Date Title
DK0679187T4 (da) Fremgangsmåde til udvinding af native, oligomere, glycosylerede ektodomæner fra virale membranproteiner, og deres anvendelse, især som vaccine mod HIV
Earl et al. Oligomeric structure of the human immunodeficiency virus type 1 envelope glycoprotein.
US6420141B1 (en) Anti-HIV immunogens (toxoids), preparation methods and use for preventing and treating aids
ES2009350A6 (es) Procedimiento para la preparacion de vectores de expresion que codifican una nueva proteina.
WO2003038057A3 (en) Genetic vaccine against human immunodeficiency virus
JP3152433B2 (ja) Ｈｉｖ感染防止用ワクチンおよび免疫療法剤
ATE373010T1 (de) Gag-antigen und dessen verwendung zum nachweis von lav-infektion, sowie in immunogenen zusammensetzungen
NO863803L (no) Vaksiner og immunoanalyser for ervervet immunsviktsyndrom (aids).
MY136081A (en) Modified hiv - 1gag p17 peptide and immunogenic composition
ATE397014T1 (de) Hiv-peptide, antigene und impfstoffzusammensetzungen
MXPA02005639A (es) Induccion de respuestas celulares iinmunologicas al virus de papiloma humano y utilizacion de composiciones de peptidos y acidos nucleico.
DE68927348D1 (de) Künstlicher impfstoff gegen aids-virus
WO2004101598A3 (en) Insertion of furin protease cleavage sites in membrane proteins and uses thereof
Weiss et al. Recombinant HIV-1 nucleocapsid protein p15 produced as a fusion protein with glutathione S-transferase in Escherichia coli mediates dimerization and enhances reverse transcription of retroviral RNA
CN1526018B (zh) 人类免疫缺陷病毒嵌合蛋白质的重组痘病毒
DK0909323T3 (da) Helicobacter pylori-bakterioferritin
UA84667C2 (ru) Вакцина, направленная против инфекции, вызванной вирусом герпеса болезни марека
Giron et al. Human foamy virus polypeptides: identification of env and bel gene products
DE60218327D1 (de) Inaktivierte immunogene bakterielle ganzzell-zusammensetzungen
ATE335745T1 (de) Verfahren zur herstellung von protease hemmenden zwischenprodukten
IL158981A0 (en) Tsg101 as inhibitor of hiv production
Barnes Strategies for an AIDS Vaccine: In their attempts to develop a vaccine against AIDS, many scientists focus on raising antibodies to a protein from the AIDS virus, a strategy that some researchers think may require modification
ATE438714T1 (de) Molekulare klone mit mutierten hiv gag/pol, siv gag und siv env gene
ATE284709T1 (de) Virale chimären aus caev und hiv-1 genetischen elementen
ATE369427T1 (de) Glykosylierungsresistente cyanovirine und damit verbundene konjugate, zusammensetzungen, nukleinsäuren, vektoren, wirtszellen, herstellungsverfahren sowie verfahren zur verwendung nichtglykosylierter cyanovirine